- Oxford Covid shot less effective against S African variant, study suggests
- Netherlands cases pass 1m
- Worcestershire begins surge testing for South African Covid variant
- UK on target to give all over-50s Covid jabs by May – taskforce chief
- When Britain might start reopening
- See all our coronavirus coverage
AstraZeneca said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African Covid variant, based on early data from a trial, Reuters reports.
The study from South Africa’s University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.
A major teaching hospital in England has been forced to suspend its vaccination clinics because it does not have enough eligible people to be vaccinated, reports the Observer’s James Tapper.